DaVita Inc. (DVA) reported $14.17B of revenue for the twelve months ended Sep 30, 2026. That is up 6.4% from the year before. Revenue for fiscal 2025 was $13.64B.

Yes. DaVita Inc. earned $920.08M in net income for the twelve months ended Sep 30, 2026, a net margin of 6.5%.

How much cash and debt does DVA have?

DaVita Inc. reported $495.63M in cash and cash equivalents and $10.66B of debt on its most recent balance sheet in SEC filings.

How fast is DVA revenue growing?

DaVita Inc.'s revenue changed +6.5% in fiscal 2025, to $13.64B. Its compound annual growth rate was +3.4% over 5 years and +3.2% over 10 years.

What is DVA free cash flow?

DaVita Inc. generated $1.29B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.87B less capital expenditures.

What is DVA earnings per share?

Diluted earnings per share were $13.51 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did DVA last report financial results?

The latest statements here come from DaVita Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Where does this DVA financial data come from?

Quantisnow builds these statements from the structured XBRL data DaVita Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · DVA

DaVita Inc. (DVA) financials

For the twelve months ended Sep 30, 2026, DaVita Inc. reported $14.17B of revenue and $920.08M of net income.

Revenue, TTM: $14.17B
Revenue growth, YoY: +6.4%
Net income, TTM: $920.08M
Net income growth, YoY: +19.2%
Net margin: 6.5%
Free cash flow, TTM: $1.29B
EPS, diluted, TTM: $13.51
EPS growth, YoY: +39.3%
Cash: $495.63M
Total debt: $10.66B
P/E: 13.08
P/S: 0.85
Market cap: $12.04B

Annual revenue$13.64B

FY2016FY2025

Annual net income$746.80M

FY2016FY2025

Annual free cash flow$1.31B

FY2016FY2025

DVA revenue and earnings growth

DVA revenueQ3 2026$3.58B

Quarter YoY: +4.6%
QoQ: +0.7%
FY YoY: +6.5%
5Y CAGR: +3.4%
10Y CAGR: +3.2%

DVA revenue was $3.58B in fiscal Q3 2026 (ended Sep 30, 2026), up 4.6% from a year earlier and up 0.7% from the prior quarter. For the full fiscal 2025 it was $13.64B, up 6.5% from fiscal 2024. Compound annual growth was +3.4% over 5 years and +3.2% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

DVA net incomeQ3 2026$222.93M

Quarter YoY: +48.3%
QoQ: -16.0%
FY YoY: -20.2%
5Y CAGR: -0.7%
10Y CAGR: +10.7%

DVA net income was $222.93M in fiscal Q3 2026 (ended Sep 30, 2026), up 48.3% from a year earlier and down 16.0% from the prior quarter. For the full fiscal 2025 it was $746.80M, down 20.2% from fiscal 2024. Compound annual growth was -0.7% over 5 years and +10.7% over 10 years. It rose in 5 of the last 10 fiscal years.

DVA EPSQ3 2026$3.40

Quarter YoY: +66.7%
QoQ: -15.4%
FY YoY: -8.3%
5Y CAGR: +9.3%
10Y CAGR: +22.9%

DVA diluted EPS was $3.40 in fiscal Q3 2026 (ended Sep 30, 2026), up 66.7% from a year earlier and down 15.4% from the prior quarter. For the full fiscal 2025 it was $9.84, down 8.3% from fiscal 2024. Compound annual growth was +9.3% over 5 years and +22.9% over 10 years.

DVA free cash flowQ3 2026$359.34M

Quarter YoY: -46.8%
QoQ: +12.2%
FY YoY: -10.6%
5Y CAGR: +0.1%
10Y CAGR: +4.4%

DVA free cash flow was $359.34M in fiscal Q3 2026 (ended Sep 30, 2026), down 46.8% from a year earlier and up 12.2% from the prior quarter. For the full fiscal 2025 it was $1.31B, down 10.6% from fiscal 2024. Compound annual growth was +0.1% over 5 years and +4.4% over 10 years. It rose in 3 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$13.64B	$12.82B	$12.14B	$11.61B	$11.62B	$11.55B	$11.39B	$11.40B	$10.88B	$10.71B
Selling, general and admin	$1.67B	$1.54B	$1.47B	$1.36B	$1.20B	$1.25B	$1.10B	$1.14B	$1.06B	$1.07B
Operating income	$2.04B	$2.09B	$1.60B	$1.34B	$1.80B	$1.69B	$1.64B	$1.53B	$1.81B	$2.03B
Pre-tax income	$1.35B	$1.53B	$1.18B	$966.28M	$1.52B	$1.32B	$1.20B	$1.05B	$1.40B	$1.62B
Income tax	$293.11M	$279.66M	$220.12M	$198.09M	$306.73M	$313.93M	$279.63M	$258.40M	$323.86M	$431.76M
Net income	$746.80M	$936.34M	$691.53M	$560.40M	$978.45M	$773.64M	$810.98M	$159.39M	$663.62M	$879.87M
EPS, basic	$10.06	$11.02	$7.62	$6.03	$9.30	$6.46	$5.29	$0.93	$3.52	$4.36
EPS, diluted	$9.84	$10.73	$7.42	$5.85	$8.90	$6.31	$5.27	$0.92	$3.47	$4.29
Diluted shares	75.9M	87.3M	93.2M	95.8M	109.9M	122.6M	153.8M	172.4M	191.3M	204.9M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$676.44M	$879.83M	$464.63M	$338.99M	$554.96M	$501.79M	$1.21B	$415.42M	$518.92M	$683.46M
Short-term investments	$24.30M	$51.06M	$11.61M	$77.69M	$22.31M	$20.10M	$11.57M	$2.94M	$32.83M	$306.98M
Receivables	$2.41B	$2.15B	$1.99B	$2.13B	$1.96B	$1.82B	$1.80B	$1.86B	$1.71B	$1.50B
Inventory	$160.63M	$134.56M	$143.10M	$109.12M	$107.43M	$111.63M	$97.95M	$107.38M	$181.80M	$160.42M
Current assets	$4.06B	$3.75B	$3.14B	$3.16B	$3.17B	$3.15B	$3.69B	$8.42B	$8.77B	$3.99B
Goodwill	$7.55B	$7.38B	$7.11B	$7.08B	$7.05B	$6.92B	$6.79B	$6.84B	$6.61B	$6.02B
Total assets	$17.48B	$17.29B	$16.89B	$16.93B	$17.12B	$16.99B	$17.31B	$19.11B	$18.97B	$18.76B
Current liabilities	$3.14B	$2.97B	$2.64B	$2.62B	$2.40B	$2.48B	$2.37B	$4.89B	$3.07B	$2.71B
Long-term debt	$10.16B	$9.18B	$8.27B	$8.69B	$8.73B	$7.92B	$7.98B	$8.17B	$9.16B	$8.94B
Total debt	$10.16B	$9.18B	$8.27B	$8.69B	$8.73B	$7.92B	$7.98B	$8.17B	$9.16B	$8.94B
Total liabilities	$16.32B	$15.19B	$14.15B	$14.70B	$14.75B	$14.09B	$13.81B	$14.08B	$13.08B	$12.93B
Shareholders' equity	-$651.08M	$121.12M	$1.06B	$712.33M	$755.51M	$1.38B	$2.13B	$3.70B	$4.69B	$4.65B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$1.89B	$2.02B	$2.06B	$1.56B	$1.93B	$1.98B	$2.07B	$1.77B	$1.91B	$1.97B
Capital expenditures	$575.86M	$555.44M	$567.99M	$603.43M	$641.47M	$674.54M	$766.55M	$987.14M	$905.25M	$829.10M
Free cash flow	$1.31B	$1.47B	$1.49B	$961.14M	$1.29B	$1.30B	$1.31B	$784.50M	$1.01B	$1.14B
Investing cash flow	-$654.95M	-$771.43M	-$771.80M	-$630.35M	-$784.73M	-$825.37M	$3.00B	-$1.01B	-$1.36B	-$1.20B
Financing cash flow	-$1.37B	-$816.94M	-$1.17B	-$1.12B	-$1.08B	-$1.85B	-$4.70B	-$625.35M	-$766.26M	-$1.35B
Dividends paid	$0	$0	$0	$0	$0	$0	$0	$0	-	-
Share repurchases	$1.31B	$1.39B	$272.22M	$802.23M	$1.54B	$1.46B	$2.38B	$1.16B	$802.95M	$1.10B
Stock-based compensation	$139.95M	$102.79M	$112.38M	$95.43M	$102.21M	$91.46M	$67.85M	$73.06M	$35.09M	$38.34M
Depreciation and amortization	$708.25M	$716.40M	$736.47M	$721.13M	$667.75M	$616.63M	$600.90M	$574.80M	$544.13M	$494.94M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	6.5%	5.6%	4.6%	-0.1%	0.6%	1.4%	-0.1%	4.9%	1.6%	7.3%
Net income growth, YoY	-20.2%	35.4%	23.4%	-42.7%	26.5%	-4.6%	408.8%	-76.0%	-24.6%	226.2%
EPS growth, YoY	-8.3%	44.6%	26.8%	-34.3%	41.0%	19.7%	472.8%	-73.5%	-19.1%	243.2%
Operating margin	15.0%	16.3%	13.2%	11.5%	15.5%	14.7%	14.4%	13.4%	16.7%	19.0%
Net margin	5.5%	7.3%	5.7%	4.8%	8.4%	6.7%	7.1%	1.4%	6.1%	8.2%
Free cash flow margin	9.6%	11.4%	12.3%	8.3%	11.1%	11.3%	11.5%	6.9%	9.3%	10.7%
Return on equity	-	773.1%	65.5%	78.7%	129.5%	55.9%	38.0%	4.3%	14.1%	18.9%
Return on assets	4.3%	5.4%	4.1%	3.3%	5.7%	4.6%	4.7%	0.8%	3.5%	4.7%
Current ratio	1.29	1.26	1.19	1.20	1.32	1.27	1.56	1.72	2.86	1.47
Debt to equity	-	75.76	7.83	12.20	11.55	5.72	3.74	2.21	1.95	1.92

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$3.58B	$3.55B	$3.42B	$3.62B	$3.42B	$3.38B	$3.22B	$3.29B	$3.26B	$3.19B	$3.07B	$3.15B
Selling, general and admin	$408.70M	$423.46M	$421.91M	$472.36M	$414.37M	$412.81M	$374.09M	$414.48M	$393.53M	$367.85M	$362.48M	$401.47M
Operating income	$499.25M	$579.00M	$481.89M	$561.07M	$505.77M	$537.84M	$438.94M	$565.36M	$534.88M	$506.40M	$483.85M	$389.91M
Pre-tax income	$358.71M	$435.01M	$341.23M	$382.76M	$308.80M	$368.93M	$286.33M	$413.73M	$373.43M	$371.44M	$371.79M	$289.07M
Income tax	$89.32M	$91.79M	$66.20M	$76.73M	$68.55M	$93.71M	$54.12M	$64.49M	$77.67M	$71.69M	$65.81M	$58.49M
Net income	$222.93M	$265.40M	$197.53M	$234.22M	$150.33M	$199.34M	$162.92M	$259.33M	$214.69M	$222.68M	$239.65M	$150.66M
EPS, basic	$3.49	$4.10	$2.93	$3.30	$2.09	$2.62	$2.05	$3.17	$2.56	$2.56	$2.73	$1.68
EPS, diluted	$3.40	$4.02	$2.87	$3.22	$2.04	$2.58	$2.00	$3.08	$2.50	$2.50	$2.65	$1.64
Diluted shares	65.5M	66.1M	68.9M	-	73.8M	77.4M	81.3M	-	85.8M	89.0M	90.5M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$495.63M	$668.96M	$644.24M	$676.44M	$795.41M	$796.96M	$524.57M	$879.83M	$1.16B	$503.25M	$430.78M	$464.63M
Short-term investments	$70.67M	$19.91M	$22.30M	$24.30M	$30.52M	$31.01M	$73.16M	$51.06M	$21.00M	$20.69M	$10.61M	$11.61M
Receivables	$2.51B	$2.47B	$2.46B	$2.41B	$2.33B	$2.44B	$2.32B	$2.15B	$2.27B	$2.30B	$2.59B	$1.99B
Inventory	$161.46M	$151.53M	$141.61M	$160.63M	$139.09M	$146.29M	$150.52M	$134.56M	$129.00M	$126.77M	$145.81M	$143.10M
Current assets	$4.07B	$4.19B	$4.06B	$4.06B	$4.11B	$4.09B	$3.64B	$3.75B	$4.04B	$3.47B	$3.68B	$3.14B
Goodwill	$7.55B	$7.59B	$7.58B	$7.55B	$7.54B	$7.47B	$7.42B	$7.38B	$7.23B	$7.20B	$7.23B	$7.11B
Total assets	$17.82B	$17.71B	$17.50B	$17.48B	$17.56B	$17.49B	$17.12B	$17.29B	$17.50B	$17.03B	$17.43B	$16.89B
Current liabilities	$2.89B	$2.86B	$2.87B	$3.14B	$3.02B	$2.93B	$2.91B	$2.97B	$2.94B	$2.99B	$2.58B	$2.64B
Long-term debt	$10.66B	$10.66B	$10.51B	$10.16B	$10.18B	$10.08B	$9.56B	$9.18B	$9.26B	$8.45B	$9.00B	$8.27B
Total debt	$10.66B	$10.66B	$10.51B	$10.16B	$10.18B	$10.08B	$9.56B	$9.18B	$9.26B	$8.45B	$9.00B	$8.27B
Total liabilities	$16.69B	$16.63B	$16.45B	$16.32B	$16.22B	$15.94B	$15.46B	$15.19B	$15.28B	$14.60B	$14.79B	$14.15B
Shareholders' equity	-$591.09M	-$765.10M	-$755.50M	-$651.08M	-$571.87M	-$369.63M	-$267.10M	$121.12M	$386.71M	$632.90M	$926.00M	$1.06B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$518.83M	$490.07M	$320.83M	$540.73M	$841.53M	$324.24M	$180.01M	$547.63M	$810.40M	$798.85M	-$134.84M	$485.20M
Capital expenditures	$159.49M	$169.82M	$102.02M	$145.43M	$166.09M	$121.09M	$143.26M	$170.66M	$139.05M	$124.72M	$121.02M	$158.97M
Free cash flow	$359.34M	$320.25M	$218.81M	$395.30M	$675.44M	$203.15M	$36.75M	$376.97M	$671.36M	$674.12M	-$255.85M	$326.23M
Investing cash flow	-$420.11M	-$194.25M	-$139.09M	-$163.13M	-$262.52M	-$67.17M	-$162.14M	-$247.97M	-$146.49M	-$161.76M	-$215.21M	-$168.30M
Financing cash flow	-$271.13M	-$270.19M	-$213.34M	-$414.52M	-$582.16M	$4.45M	-$382.54M	-$565.10M	-$7.86M	-$563.29M	$319.32M	-$403.25M
Share repurchases	$73.01M	$181.48M	$196.37M	$274.48M	$240.05M	$283.67M	$510.16M	$365.38M	$407.94M	$361.65M	$250.96M	$272.22M
Stock-based compensation	$29.19M	$26.03M	$28.16M	$38.39M	$38.99M	$32.81M	$29.76M	$27.40M	$26.56M	$24.29M	$24.54M	$30.06M
Depreciation and amortization	$165.19M	$167.81M	$177.83M	$179.61M	$177.49M	$174.70M	$176.45M	$166.64M	$187.01M	$175.66M	$187.08M	$186.31M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	4.6%	5.2%	6.0%	9.9%	4.8%	6.1%	5.0%	4.7%	4.6%	6.2%	6.9%	7.8%
Net income growth, YoY	48.3%	33.1%	21.2%	-9.7%	-30.0%	-10.5%	-32.0%	72.1%	-13.0%	24.6%	107.4%	121.2%
EPS growth, YoY	66.7%	55.8%	43.5%	4.5%	-18.4%	3.2%	-24.5%	87.8%	-4.6%	30.9%	112.0%	102.5%
Operating margin	14.0%	16.3%	14.1%	15.5%	14.8%	15.9%	13.6%	17.2%	16.4%	15.9%	15.8%	12.4%
Net margin	6.2%	7.5%	5.8%	6.5%	4.4%	5.9%	5.1%	7.9%	6.6%	7.0%	7.8%	4.8%
Free cash flow margin	10.0%	9.0%	6.4%	10.9%	19.7%	6.0%	1.1%	11.4%	20.6%	21.2%	-8.3%	10.4%
Current ratio	1.41	1.47	1.42	1.29	1.36	1.39	1.25	1.26	1.37	1.16	1.43	1.19
Debt to equity	-	-	-	-	-	-	-	75.76	23.95	13.35	9.72	7.83

Source: XBRL data DaVita Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Nov 6, 2013.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DVA peers

Company	Revenue	Growth	Net income	Net margin	Market cap
DVA	$14.17B	+6.4%	$920.08M	6.5%	$12.04B
FMSFresenius Medical Care AG	€19.63B	+1.5%	€978.37M	5.0%	$13.07B
SHCSotera Health Company	$1.23B	+6.9%	$173.47M	14.1%	$4.57B
PGNYProgyny Inc.	$1.34B	+5.5%	$91.02M	6.8%	$2.67B
AGLagilon health inc.	$6.00B	+2.0%	-$87.10M	-1.5%	$1.90B
VMDViemed Healthcare Inc.	$310.37M	+21.8%	$15.89M	5.1%	$346.0M
CCELCryo-Cell International Inc.	$31.13M	-2.0%	-$1.95M	-6.2%	$39.4M
NIVFNewGenIvf Group Limited	$23.71M	+336.3%	$9.88M	41.7%	$4.5M

DVA FAQ

8 questions

What is DVA revenue?
DaVita Inc. (DVA) reported $14.17B of revenue for the twelve months ended Sep 30, 2026. That is up 6.4% from the year before. Revenue for fiscal 2025 was $13.64B.
Is DVA profitable?
Yes. DaVita Inc. earned $920.08M in net income for the twelve months ended Sep 30, 2026, a net margin of 6.5%.
How much cash and debt does DVA have?
DaVita Inc. reported $495.63M in cash and cash equivalents and $10.66B of debt on its most recent balance sheet in SEC filings.
How fast is DVA revenue growing?
DaVita Inc.'s revenue changed +6.5% in fiscal 2025, to $13.64B. Its compound annual growth rate was +3.4% over 5 years and +3.2% over 10 years.
What is DVA free cash flow?
DaVita Inc. generated $1.29B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.87B less capital expenditures.
What is DVA earnings per share?
Diluted earnings per share were $13.51 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did DVA last report financial results?
The latest statements here come from DaVita Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this DVA financial data come from?
Quantisnow builds these statements from the structured XBRL data DaVita Inc. files with the SEC. It is provided for information only and is not investment advice.